Minority report: Hidden memory genomes in HIV-1 quasispecies and possible clinical implications

AIDS Reviews

Volumn 10, Issue 2, 2008, Pages 93-109

  Briones, Carlos ^a,b   Domingo, Esteban ^a,b,c  

^a CENTRO DE ASTROBIOLOGÍA CSIC INTA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c CSIC   (Spain)

Author keywords

DNA microarrays; Drug resistance; Intrahost evolution; Persisting minority variants; Pyrosequencing; Quasispecies memory; Reemergence

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; DIDANOSINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

BIOSENSOR; CD4+ T LYMPHOCYTE; CONSENSUS SEQUENCE; DNA MICROARRAY; DRUG SENSITIVITY; FOOT AND MOUTH DISEASE VIRUS; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEMORY GENOME; MOLECULAR DYNAMICS; MOLECULAR MEMORY; MULTIDRUG RESISTANCE; NANOTECHNOLOGY; NONHUMAN; PHYLOGENY; PYROSEQUENCING; REPLICATIVE MEMORY; RESERVOIR MEMORY; RETROVIRUS; REVIEW; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION;

GENOME, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; POLYMORPHISM, GENETIC; RNA, VIRAL; SELECTION (GENETICS);

EID: 48449092074     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (145)

1. Drake J. Rates of spontaneous mutations among RNA viruses. Proc Natl Acad Sci USA. 1993;90:4171-5.
2. Drake J, Holland J. Mutation rates among RNA viruses. Proc Natl Acad Sci USA. 1999;96:13910-13.
3. Eigen M. Self-organization of matter and evolution of biological macromolecules. Naturwissenschaften. 1971;58:465-523.
4. Eigen M, Schuster P. The hypercycle. A principle of natural self-organization. Berlin: Springer 1979.
5. Eigen M. On the nature of virus quasispecies. Trends Microbiol. 1996;4: 216-18.
6. Domingo E. Virus Evolution. In: Knipe D, Howley P, eds. Fieds' Virology Filadelfia (PA): Lippincott-Williams & Wilkins 2007:389-421.
7. Eigen M, Biebricher C. Sequence space and quasispecies distribution. In RNA Genetics (Domingo E, Ahlquist P, Holland J, eds). Boca Ratón, FL: CRC 1988;3:211-45.
8. Domingo E, Holland J. RNA virus mutations and fitness for survival. Annu Rev Microbiol. 1997;51:151-78.
9. Domingo E, Biebricher C, Holland J, Eigan M. Quasispecies and RNA virus evolution: principles and consequences. Austin, TX: Landes Bioscience 2001.
10. Domingo E. Viruses at the edge of adaptation. Virology. 2000;270:251-3.
11. Domingo E, Martin V, Perales C, Grande-Pérez A, García-Arriaza J, Arias A. Ouasispecies: concepts and implications for virology. Curr Top Microbiol Immunol. 2006;299:51-82.
12. Vignuzzi M, Stone J, Arnold J, Cameron C, Andino R. Quasispecies diversity determines pathogenesis through cooperative interactions within a viral population Nature. 2006;439:344-8.
13. Stich M, Briones C, Manrubia S. Collective properties of evolving molecular quasispecies. BMC Evol Biol. 2007;7:110.
14. Pawlotsky J, Germanidis G, Neumann A, Pellerin M, Frainais P, Dhumeaux D. Interferon resistance of HCV genotype 1b: relationship tonon-structural 5A gene quasispecies mutations. J Virol. 1998; 72:2795-805.
15. Ciota A, Ngo K, Lovelace A, et al. Role of the mutant spectrum in adaptation and replication of West Nile virus. J Gen Virol. 2007; 88:865-74.
16. Jerzak G, Bernard K, Kramer L, Shi P-Y, Ebel G. The West Nile virus mutant spectrum is host-dependant and a determinant of mortality in mice. Virology. 2007;360:469-76.
17. Borrow P, Lewicki H, Wei X, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med. 1997;3:205-11.
18. Wyatt C, Andrus L, Brotman B, Huang F, Lee D, Prince A. Immunity in chimpanzees chronically infected with HCV: role of minor quasispecies in reinfection. J Virol. 1998;72:1725-30.
19. Karlsson A, Gaines H, Sallberg M, Lindback S, Sonnerborg A. Reappearance of founder virus sequence in HIV-1-infected patients. J Virol. 1999;73:6191-6.
20. Lau D, Khokhar M, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology. 2000;32:828-34.
21. García-Lerma J, Nidtha S, Blumoff K, Weinstock H, Heneine W. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Natl Acad Sci USA. 2001;98:13907-12.
22. Arlen P, Brooks D, Gao L, Vatakis D, Brown H, Zack J. Rapid expression of HIV following activation of latently infected cells. J Virol. 2006;80:1599-603.
23. Sagar M, Kirkegaard E, Lavreys L, Overbaugh J. Diversity in HIV-1 envelope V1-V3 sequences early in infection reflects sequence diversity throughout the HIV-1 genome but does not predict the extent of sequence diversity during chronic infection. AIDS Res Hum Retroviruses. 2006;22:430-7.
24. Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using HIV-1 variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist Maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol. 2006;80:4909-20.
25. Nájera I, Richman D, Olivares I, et al. Natural occurrence of drug resistance mutations in the reverse transcriptase of HIV-1 isolates. AIDS Res Hum Retroviruses. 1994;10:1479-88.
26. Nájera I, Holguín A, Quiñones-Mateu M, et al. Pol gene quasispecies of HIV: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol. 1995;69:23-31.
27. Nakano T, Morozumi H, Inuzuka S, et al. Clonal selection of HIV type 1 variants associated with resistance to foscarnet in vitro: confirmation by molecular evolutionary analysis. AIDS Res Hum Retroviruses. 1997;13: 563-73.
28. Briones C, Soriano V. Different outcome in the first two patients with an HIV-1 multi-nucleoside drug-resistant T69SSS insertion in Spain. Antivir Ther. 1999;4:125-7.
29. Briones C, Mas A, Gómez-Mariano G, et al. Dynamics of dominance of a dipeptide insertion in reverse transcriptase of HIV-1 from patients subjected to prolongued therapy. Virus Res 2000; 66:13-26.
30. Paolucci S, Baldanti F, Campanini G, et al. Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients. J Med Virol. 2001;65: 207-17.
31. Charpentier C, Dwyer D, Mammano F, Lecossier D, Clavel F, Hance A. Role of minority populations of HIV-1 in the evolution of viral resistance to protease inhibitors. J Virol. 2004;78:4234-47.
32. Vandamme A, Sonnerborg A, Ait-Khaled M, et al. Updated European recommendations for the clinical use of HIV drug resistance testing Antivir Ther. 2004;9:829-48.
33. Lecossier D, Shulman N, Morand-Joubert L, et al. Detection of minority populations of HIV-1 expressing the K103N resistance mutations in patients failing nevirapine. J Acquir Immune Defic Syndr. 2005;38:37-42.
34. Allers K, Knoepfe L, Rauch P, et al. Persistence of lamivudine-sansitive HIV-1 quasispecies in the presence of lamivudine in vitro and in vivo. J Acquir Immune Defic Syndr. 2007;44:377-85.
35. Kolber M. Development of drug resistance mutations in patients on HAART: does competitive advantage drive evolution? AIDS Rev. 2007; 9:68-74.
36. Cai F, Chen H, Hicks C, Bartlett J, Zhu J, Gao F. Detection of minor drug-resistant populations by parallel allele-specific sequencing. Nat Methods. 2007;4:123-5.
37. Metzner K, Allers K, Rauch P, Harrer T. Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients. AIDS. 2007;21:703-11.
38. Johnson V, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med. 2007;15:119-25.
39. Louvel S, Battegay M, Vernazza P, et al. Detection of drug-resistant HIV minorities in clinical specimens and therapy failure. HIV Med. 2008;9:133-41.
40. Imamichi H, Crandall K, Natarajan V, et al. HIV-1 quasispecies that rebound after discontinuation of HAART are similar to the viral quasispecies present before initiation of therapy. J Infect Dis. 2001;183:36-50.
41. Hance A, Lemiale V, Izopet J, et al. Changes in HIV-1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol. 2001;75:6410-7.
42. Kijak G, Simon V, Balfe P. Origin of HIV-1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure. J Virol. 2002;76:7000-9.
43. Izopet J, Souyris C, Hance A, et al. Evolution of HIV-1 populations after resumption of therapy following treatment interruption and shift in resistant genotype. J Infect Dis. 2002;185:1506-10.
44. Metzner K, Bonhoeffer S, Fischer M, et al. Emergence of minor populations of HIV-1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis. 2003;188: 1433-43.
45. Boucher S, Recordon-Pinson P, Neau D, et al. Clonal analysis of HIV-1 variants in proviral DNA during treatment interruption in patients with multiple therapy failures. J Clin Virol. 2005;34:288-94.
46. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2007;351: 229-40.
47. Lockman S, Shapiro R, Smeaton L, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007;356:135-47.
48. Ruiz-Jarabo C, Arias A, Baranowski E, Escarmís C, Domingo E. Memory in viral quasispecies. J Virol. 2000;74:3543-7.
49. Ruiz-Jarabo C, Arias A, Molina-París C, et al. Duration and fitness dependence of quasispecies memory. J Mol Biol. 2002; 315:285-96.
50. Briones C, Domingo E, Molina-París C. Memory in retroviral quasispecies: experimental evidence and theoretical model for HIV. J Mol Biol. 2003;331:213-29.
51. Briones C, Bastolla U. Protein evolution in viral quasispecies under selective pressure: a thermodynamic and phylogenetic analysis. Gene. 2005;347:237-46.
52. Briones C, de Vicente A, Molina-París C, Domingo E. Minority memory genomes can influence the evolution of HIV-1 quasispecies in vivo. Gene. 2006;384:129-38.
53. Fazilleau N, Eisenbraun M, Malherbe L, et al. Lymphoid reservoirs of antigen-specific memory T helper cells. Nat Immunol. 2007;8:753-61.
54. Ruíz-Jarabo C, Miller E, Gómez-Mariano G, Domingo E. Synchronous loss of quasispecies memory in parallel viral lineages: a deterministic feature of viral quasispecies. J Mol Biol. 2003;333: 553-63.
55. Arias A, Ruiz-Jarabo C, Escarmis C, Domingo E. Fitness increase of memory genomes in a viral quasispecies. J Mol Biol. 2004;339:405-12.
56. Novella I, Clarke D, Quer J, et al. Extreme fitness differences in mammalian and insect hosts after continuous replication of vesicular stomatitis virus in sandfly cells. J Virol. 1995;69:6805-9.
57. Escarmís C, Dávila M, Domingo E. Multiple molecular pathways for fitness recovery of an RNA virus debilitated by operation of Muller's ratchet. J Mol Biol. 1999;285:495-505.
58. Clarke D, Duarte E, Elena S, Moya A, Domingo E, Holland J. The red queen reigns in the kingdom of RNA viruses. Proc Natl Acad Sci USA. 1994;91:4821-4.
59. Pantaleo G, Graziosi C, Butini L. Lymphoid organs function as major reservoirs for HIV. Proc Natl Acad Sci USA. 1991;88:9838-42.
60. Finzi D, Hermankova M, Pierson T. Identification of a reservoir for HIV-1 in patients on HAART. Science. 1997;278:1295-300.
61. Pierson T, McArthur J, Siliciano R. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol. 2000; 18:665-708.
62. Blankson J, Persaud D, Siciliano R. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med. 2002;53:557-93.
63. Kulkosky J, Bray S. HAART-persistent HIV-1 latent reservoirs: their origin, mechanisms of stability and potential strategies for eradication. Curr HIV Res. 2006;4:199-208.
64. Koelsch K, Liu L, Haubrich R, et al. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis. 2008;197:411-9.
65. Friedberg E, Walker G, Siede W. DNA repair and mutagenesis. Washington DC: American Society of Microbiology. 1995.
66. Crandall K. The Evolution of HIV. Baltimore and London: The Johns Hopkins University Press. 1999.
67. Goff S. Intracellular trafficking of retroviral genomes during the early phase of infection: viral exploitation of cellular pathways. J Gene Med. 2001;3:517-28.
68. Devereux HL, Burke A, Lee CA, Johnson, MA. In vivo HIV-1 compartmentalization: drug resistance-associated mutation distribution. J Med Virol. 2002;66:8-12.
69. Ruff C, Ray S, Kwon P, et al. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for HIV-1 in pediatric patients with extensive antiretroviral exposure. J Virol. 2002; 76:9481-92.
70. Shehu-Xhilaga M, Tachedjian G, Crowe S, Kedzierska K. Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1. Curr Med Chem. 2005;12:1705-19.
71. Deeks S, Grant R, Wrin T, et al. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS. 2003;17:361-70.
72. Briones C, Soriano V, González-Lahoz J. Prevalence of drug-resistant HIV-1 genotypes in heavily pretreated patients on current virologic failure. AIDS. 2000;14:1659-60.
73. De Antoni A, Foli A, Lisziewicz J, Lori F. Mutations in the pol gene of HIV-1 in infected patients receiving didanosine and hydroxyurea combination therapy. J Infect Dis. 1997;176:899-903.
74. Tamalet C, Yahi N, Tourrès C, et al. Multidrug resistance genotypes (insertions in the β3-β4 finger subdomain and MDR mutations) of HIV-1 reverse transcriptase from extremely treated patients: Incidence and association with other resistance mutations. Virology. 2000;270:310-6.
75. Winters M, Coolley K, Girard Y, et al. A 6-base pair insert in the reverse transcriptase gene of HIV-1 confers resistance to multiple nucleoside inhibitors. J Clin Invest. 1998;102:1769-75.
76. Mas A, Parera M, Briones C, et al. Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance, EMBO J. 2000;19:5752-61.
77. Chun T, Davey R, Ostrowski M, et al. Relationship between preexisting viral reservoirs and the re-emergence of plasma viremia after discontinuation of HAART. Nat Med. 2000;6:757-61.
78. Frost S, Martínez-Picado J, Ruiz L, Clotet B, Brown A. Viral dynamics during structured treatment interruptions of chronic HIV-1 infection. J Virol. 2002;76:968-79.
79. Balduin M, Sierra S, Däumer MP, et al. Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy. J Clin Virol. 2005;34:277-87.
80. Shafer R, Kozal M, Winters M, et al. Combination therapy with zidovudine and didanosine selects for drug-resistant HIV-1 strains with unique patterns of pol gene mutations. J Infect Dis. 1994;169:722-9.
81. Shirasaka T, Kavlick M, Ueno T, et al. Emergence of HIV-1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA. 1995;92: 2398-402.
82. Ueno T, Shirasaka T, Mitsuya H. Enzymatic characterization of HIV-1 reverse transcriptase resistant to multiple 2′,3′-dideoxynucleoside 5′-triphosphates. J Biol Chem. 1995;270:23605-11.
83. Kosalaraksa P, Kavlick M, Maroun V, Le R, Mitsuya H. Comparative fitness of multi-dideoxynucleoside-resistant HIV-1 in an in vitro competitive HIV-1 replication assay. J Virol. 1999;73:5356-63.
84. Novella I, Duarte E, Elena S, Moya A, Domingo E, Holland J. Exponential increases of RNA virus fitness during large population transmissions. Proc Natl Acad Sci USA. 1995;92:5841-4.
85. Martinez-Picado J, Martínez M. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: A view from the clinic and ex vivo. Virus Res. 2008;134:104-23.
86. Clementi M. Can modulation of viral fitness represent a target for anti-HIV-1 strategies? New Microbiol. 2004;27:207-14.
87. Coffin J. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy Science. 1995;267:483-9.
88. Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, de Groot T, Boucher C. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in HIV-1 reverse transcriptase. J Clin Microbiol. 1999;37:2291-6.
89. Frater A, Chaput C, Weber J, McClure M. HIV-1 resistance genotyping by sequencing produces inconsistent results for mixed viral populations. AIDS. 2000;14:1473-5.
90. Shafer RW. Genotyping testing for HIV-1 drug resistance. Clin Microbiol Rev. 2002;15:247-77.
91. Palmer S, Kearney M, Mandarelly F, et al. Multiple, linked HIV-1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol. 2005;43:406-13.
92. Stuyver L, Wyseur A, Rombout A. Line probe assay for rapid detection of drug-selected mutations in the HIV-1 reverse transcriptase gene. Antimicrob Agents Chemother. 1997;41:284-91.
93. van Laethem K, van Vaerenbergh K, Schmit J, et al. Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. J Acquir Immune Defic Syndr. 1999;22:107-18.
94. Wilson J, Bean P, Robins T, Graziano F, Persing D. Comparative evaluation of three HIV genotyping systems: the HIV-GenotypR Method, the HIV PRT GeneChip Assay, and the HIV-1 RT Line Probe Assay. J Clin Microbiol. 2000;38:3022-28.
95. Halvas E, Aldrovandi C, Balfe P, et al. Blinded, multicenter comparison of methods to detect a drug-resistant mutant of HIV-1 at low frequency. J Clin Microbiol. 2006;44:2612-4.
96. Castro E, Bélair M, Rizzardi G, Bart P, Pantaleo G, Graziosi C. Independent evolution of hypervariable regions of HIV-1 gp120: V4 as a swarm of N-Linked glycosylation variants. AIDS Res Hum Retroviruses. 2008; 24:106-13.
97. García-Arriaza J, Domingo E, Briones C. Characterization of minority subpopulations in the mutant spectrum of HIV-1 by successive specific amplifications. Virus Res. 2007;129:123-34.
98. Edelstein R, Nickerson D, Tobe V, Manns-Arcuino L, Frenkel L. Oligonucleotide ligation assay for detecting mutations in the HIV-1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine. J Clin Microbiol. 1998;36:569-72.
99. Ellis G, Mahalanabis M, Beck I, et al. Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of HIV-1 in peripheral blood mononuclear cells and plasma. J Clin Microbiol. 2004;42:3670-4.
100. Barlow K, Green J, Clewley J. Viral genome characterization by the heteroduplex mobility and heteroduplex tracking assays. Rev Med Virol. 2000;10:321-35.
101. Resch W, Parkin N, Stuelke E, Watkins T, Swanstrom R. A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics. Proc Natl Acad Sci USA. 2001;98: 176-81.
102. Doukhan L, Delwart E. Population genetic analysis of the protease locus of HIV-1 quasispecies undergoing drug selection, using a denaturing gradient-heteroduplex tracking assay. J Virol. 2001;75: 6729-36.
103. Kapoor A, Jones M, Shafer R, Rhee S-Y, Kazanjian P, Delwart E. Sequencing-based detection of low-frequency HIV-1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay. J Virol. 2004;78:7112-23.
104. Charpentier C, Dwyer D, Mammano F, Lecossier D, Clavel F, Hance A. Role of minority populations of HIV-1 in the evolution of viral resistance to protease inhibitors. J Virol. 2004;78:4234-7.
105. Bergroth T, Sonnerborg A, Yun Z. Discrimination of lamivudine resistant minor HIV-1 variants by selective real-time PCR. J Virol Methods. 2005; 127:100-7.
106. Metzner K, Raunch P, Walter H, et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS. 2005; 19:1819-25.
107. Margulies M, Egholm M, Altman W, et al. Genome sequencing in micro-fabricated high-density picolitre reactors. Nature. 2005;437:376-80.
108. Lindström A, Odeberg J, Albert J. Pyrosequencing for detection of lamivudine-resistant HBV. J Clin Microbiol. 2004;42:4788-95.
109. Kramski M, Meisel H, Klempa B, Krüger D, Pauli G, Nitsche A. Detection and typing of human pathogenic hantaviruses by real-time reverse transcription-PCR and pyrosequencing. Clin Chem. 2007;53:1899-905.
110. Deyde V, Xu X, Bright R, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis. 2007;196:249-57.
111. Palacios G, Druce J, Du L, et al. A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med. 2008;358:991-8.
112. O'Meara D, Wilbe K, Leitner T, Hejdeman B, Albert J, Lundeberg J. Monitoring resistance to HIV-1 protease inhibitors by pyrosequencing. J Clin Microbiol. 2001;39:464-73.
113. Wang G, Ciuffi A, Leipzig J, Berry C, Bushman F. HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res. 2007;17:1186-94.
114. Hoffmann C, Minkah N, Leipzig J, et al. DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. Nucleic Acids Res. 2007;35:e91.
115. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer R. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res. 2007;17: 1195-201.
116. Eriksson N, Pachter L, Mitsuya Y, et al. Viral population estimation using pyrosequencing. PLoS Comput Biol. 2008;4:e1000074.
117. Shendure J, Mitra R, Varma C, Church G. Advanced sequencing technologies: Methods and goals. Nat Rev Genet. 2004; 5:335-44.
118. Thomas R, Nickerson E, Simons J, et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med. 2006;12:852-5.
119. Southern E. Arrays of complementary oligonucleotides for analyzing the hybridization behavior of nucleic acids. Nucleic Acids Res. 1994;22: 1368-72.
120. Hacia J, Makalowski W, Edgemon K, et al. Evolutionary sequence comparisons using high-density oligonucleotide arrays. Nat Gen. 1998;18: 155-8.
121. Schena M. Ed., Microarray biochip technology, Eaton Publishing: Sunnyvale, CA, 2000.
122. Levicky R, Horgan A. Physicochemical perspectives on DNA microarray and biosensor technologies. Trends Biotechnol. 2005;3:143-9.
123. Bryant P, Venter D, Robins-Browne R, Curtis N, et al. Chips with everything: DNA microarrays in infectious diseases. Lancet Infect Dis. 2004;4:100-11.
124. Li J, Chen S, Evans DH. Typing and subtyping influenza virus using DNA microarrays and multiplex reverse transcriptase PCR. J Clin Microbiol. 2001;39:696-704.
125. Sengupta S, Onodera K, Lai A, Melcher U. Molecular detection and identification of influenza viruses by oligonucleotide microarray hybridization. J Clin Microbiol. 2003;41:4542-50.
126. Ivshina A, Vodeiko G, Kuznetsov V, et al. Mapping of genomic segments of influenza B virus strains by an oligonucleotide microarray method. J Clin Microb. 2004;42:5793-801.
127. Perrin A, Duracher D, Perret M, Cleuziat P, Mandrand B. A combined oligonucleotide and protein microarray for the co-detection of nucleic acids and antibodies associated with HIV, HBV, and HCV infections. Anal Biochem. 2003;322:148-55.
128. Song Y, Dai E, Wang J, et al. Genotyping of HBV by oligonucleotides microarray. Mol Cell Probes. 2006;20:121-7.
129. Hsia C, Chizhikov V, Yang A, et al. Microarray multiplex assay for the simultaneous detection and discrimination of HBV, HCV, and HIV-1 viruses in human blood samples. Biochem Biophys Res Commun. 2007; 356:1017-23.
130. Chizhikov V, Wagner M, Ivshina A, Hoshino Y, Kapikian A, Chumakov K. Detection and genotyping of human group A rotaviruses by oligonucleotide microarray hybridization. J Clin Microbiol. 2002; 40:2398-407.
131. Wang D, Coscoy L, Zylberberg M, et al. Microarray-based detection and genotyping of viral pathogens. Proc Natl Acad Sci USA. 2002;99: 15687-92.
132. Bodrossy L, Sessitsch A. Oligonucleotide microarrays in microbial diagnostics. Curr Opin Microbiol. 2004;7:245-54.
133. Gemignani F, Landi S, Chabrier A, et al. Generation of a DNA microarray for determination of E6 natural variants of human papillomavirus type 16. J Virol Methods. 2004;119:95-102.
134. Martín V, Perales C, Abia D, Ortiz A, Domingo E, Briones C. Microarray-based identification of antigenic variants of foot-and-mouth disease virus: a bioinformatics quality assessment. BMC Genomics. 2006;7:117.
135. Cherkasova E, Laassri M, Chizhikov V, et al. Microarray analysis of evolution of RNA viruses: evidence of circulation of virulent highly divergent vaccine-derived polioviruses. Proc Natl Acad Sci USA. 2003;100: 9398-403.
136. Ooms M, Verhoef K, Southern E, Huthoff H, Berkhout B. Probing alternative foldings of the HIV-1 leader RNA by antisense oligonucleotide scanning arrays. Nucleic Acids Res. 2004;32:819-27.
137. Martell M, Briones C, de Vicente A, et al. Structural analysis of hepatitis C RNA genome using DNA microarrays. Nucleic Acids Res. 2004; 32:e90.
138. Kozal M, Shah N, Shen N, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med. 1996;2:753-9.
139. Amexis G, Oeth P, Abel K, et al. Quantitative mutant analysis of viral quasispecies by chip-based matrix- assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Natl Acad Sci USA. 2001;98: 12097-102.
140. Schanné M, Bodem J, Gerhold-Ay A, et al. Genotypic resistance testing in HIV by arrayed primer extension. Anal Bioanal Chem 2008 [Epub ahead of print].
141. Gerry N, Witowski N, Day J, Hammer R, Barany G, Barany, F. Universal DNA microarray method for multiplex detection of low abundance point mutations. J Mol Biol. 1999;292:251-62.
142. Buetow K, Edmonson M, MacDonald R, et al. High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Natl Acad Sci USA. 2001;16:581-4.
143. Tillib S, Mirzabekov A. Advances in the analysis of DNA sequence variations using oligonucleotide microchip technology. Curr Opin Biotechnol. 2001;12:53-8.
144. Briones C, Martín-Gago JA. Nucleic acids and their analogs as nanomaterials for biosensor development. Current Nanoscience. 2006;2: 257-73.
145. Mertens J, Rogero C, Calleja M, et al. Label-free detection of DNA hybridization based on hydration-induced tension in nucleic acid films. Nature Nanotechnol. 2008;3:301-7.